Examination of the atherosclerotic plaque reveals the abundant presence of cholesterol in various forms: crystals of cholesterol monohydrate, extracellular perifibrillar lipid and intracellular cholesteryl ester droplets. Where this lipid comes
from, what causes its accumulation and how it can be removed are questions that have received much attention over the last 30 years, and they continue to be areas of active interest. There is little doubt that the majority of the sterol in artery walls is deposited as a byproduct of plasma lipid metabolism. Fat in the blood is carried in lipoproteinspseudomicellar structures that contain a hydrophobic core of cholesteryl ester and triglyceride, and an amphipathic coat of phospholipid, unesterified cholesterol and apoproteins. These are synthesized by the intestine gut and liver, and facilitate the transport of gram quantities of lipid to sites where it is required for membrane synthesis, bile acid production, energy generation or storage. The metabolic fate of lipoproteins is governed by certain key elements: apolipoproteins, cell membrane receptors and plasma enzymes. When these fail to operate efficiently, or when the system is overloaded by excessive dietary fat intake, misdirection of even small amounts of cholesterol can lead, over years, to the genesis of atherosclerosis.
Cholesterol and atherosclerosis
Recent national surveys of coronary risk factors have shown that about 70% of middle-aged men and women have cholesterol levels above the recommended value 1-3 of 5.2mmol/1, while onethird have a concentration in excess of 6.Smmo1/1 and are considered at significant risk of ischaemic heart disease (IHD). These findings have prompted calls for a general population-based strategy4 for lowering cholesterol levels through diet and health education. However, for some of those at the top end of the cholesterol distribution such an approach is inadequate. One in 500 of the population suffer from familial hypercholesterolaemia (FH), an inherited autosomal codominant condition that leads to a two to threefold elevation of plasma cholesterol and severe, premature cardiovascular disease.5
Individuals with the disorder do not respond well to diet, and usually require lipid-lowering drugs to significantly reduce their IHD risk. Since high cholesterol levels do not generally result in signs or symptoms of disease prior to appearance of coronary problems, the detection of subjects at risk can only be achieved through large scale screening exercises.
The issue of coronary screening for raised cholesterol and other risk factors (smoking, raised blood pressure, family history etc.) is at present contentious. Models6 have been developed in which much of the initial risk factor assessment and follow-up is handled by specially trained nurses. These systems, however, are expensive to operate and need to be evaluated carefully before they are put into widespread use. Cholesterol measurement by itself has only limited ability to identify those at risk, the difference in IHD incidence between the top and bottom quintiles of the cholesterol distribution being only 2-2.5-fold. 1,3 Better discrimination is obtained if the lipoprotein profile of very low, low and high density lipoprotein (VLDL, LDL, HDL) is assessed. Each fraction carries cholesterol but has a different impact on the atherogenic process. Furthermore, techniques have been developed recently to subfractionate each of the main plasma lipoprotein classes on the basis of size and density. Application of these methods has revealed an unexpected complexity in lipoprotein structure and function, 17 raising the possibility that the atherogenic or antiatherogenic properties of a fraction may reside in one of these specific subpopulations of particles. The discussion which follows describes advances in our understanding of the role that lipoproteins and their subfractions play in atherogenesis. Increasing knowledge in this area will improve our ability to identify the patient at risk for IHD, and to tailor treatment for his or her particular problem.
Low density lipoprotein and atherosclerosis . The level of LDL, the major cholesterol carrier in plasma, is positively correlated with the incidence of IHD. Furthermore, clinical trials have shown that when the concentration of this lipoprotein is reduced there is a lack of progression or even a regression of atherosclerosis,g and fewer signs and symptoms of IHD.9 The normal function of LDL is to carry cholesterol to hepatic and peripheral tissues where it is used for membrane assembly, bile acid synthesis and steroid hormone production. Apolipoprotein B on the LDL particle's surface facilitates the transport process by interacting with specific high-affinity receptors on cell membranes. These promote endocytosis of the lipoprotein, leading to hydrolysis of its component parts and release of cholesterol for the cell's needs. When sufficient sterol is present in a cell, synthesis of the LDL receptor is suppressed.l° Transport of cholesterol by this mechanism operates throughout the animal kingdom and in several human populations (such as the Japanese)11 at relatively low plasma LDL cholesterol concentrations, i.e. 0.5-2.0mmol/1. If it is overburdened with sterol through excessive dietary intake, or if a genetic disease such as familial hypercholesterolaemia disrupts its efficient functioning, the receptor pathway is shut down and the lipoprotein is redirected to receptor-independent, potentially atherogenic catabolic routes. The nature of the latter is unknown, although there is evidence to suggest that cells of the monocyte-macrophage series are active in the degradation of LDL by nonreceptor mechanisms.12,13 These cells are, of course, also believed to play an important role in the early stages of atherogenesis, 14 and so their interaction with lipoproteins has been intensively studied both in vitro and in vivo. Initial experiments showed that macrophages exposed to high concentrations of plasma LDL did not avidly assimilate the lipoprotein or store cholesterol, and so it was suggested that LDL had to be altered in some way before it was recognized by these cells. Further studies found that a modification of potential physiological significance was induced by endothelial cells; LDL incubated with endothelial monolayers for 24-48 hours undergoes oxidation, and this renders it susceptible to uptake by macrophages. 16 These in vitro observations suggested a sequence of events that might lead to cholesterol deposition in the artery wall, that is, LDL passing through endothelial cells in the process of transcytosis would be oxidized and hence avidly assimilated by macrophages present in the intimal layer. If the plasma LDL concentration was high enough, this pathway might proceed at a rate sufficient to generate cholesterol-laden foam cells in the subendothelial layer. These would form the focus of a growing lesion. 17
This picture of the role of LDL in the atherosclerotic process has been complicated by the demonstration that the lipoprotein class actually comprises a small number of overlapping species that vary in size and density. At least three subfractions (LDL-I to LDL-III) can be isolated from the plasma of normal and hyperlipidaemic subjects.'A LDL-I, the largest and least dense, is present in high concentration in low-risk individuals like young women, while LDL-III, (the smallest, densest particles), are abundant in patients suffering from IHD (Griffin et al. unpublished observations). Metabolic studies'9
indicate that larger LDL are catabolized more readily by receptors, while a disproportionate amount of smaller LDL is channelled to a receptor-independent mechanism. The latter, therefore, appear to represent a particularly atherogenic variety of LDL. Including their measurement in risk assessment may help explain why subjects with apparently similar general risk profiles and total LDL cholesterol levels can develop IHD at widely differing rates. It has become clear from recent studies, 20 that hypolipidaemic drugs, as well as reducing plasma cholesterol and triglyceride levels, have an impact on the structure and function of LDL particles. Bezafibrate therapy in hypertriglyceridaemics, for example, results in an increase in the average size of LDL and a change in the conformation of apolipoprotein B so that it exhibits a higher affinity for receptors. An explanation for these effects is that the drug increases the proportion of LDL-I to LDL-III in the patient's plasma. According to the above argument this should reduce the atherogenicity of the lipoprotein fraction.
Lipoprotein(a) (Lp(a)) is an LDL-like particle isolated in the density range between LDL and HDL, (i.e. 1.05-1.08g/ml). It is emerging as a new, independent risk factor for IHD, and certain aspects of its structure suggest how it may act as such. The unique feature of Lp(a) is the apolipoprotein(a) moiety which is attached to an LDL particle via a disulphide bond. This protein is of high molecular weight and has a remarkable homology with plasminogen. It contains in excess of 37 sulphydryl-linked 'kringle' structures, and an inactive 'protease' region.21 The similarity to an important component of the thrombolytic process raises the possibility that Lp(a) may increase atherosclerosis risk not only because of its LDL-like properties, but also by interfering with the activation of plasminogen. Evidence for such an effect has been published recently.22 The importance of Lp(a) as an independent risk marker for IHD was highlighted in a study in familial hypercholesterolaemic patients.23 It was found that the presence of increased Lp(a) concentrations discriminated between those who had and those who did not have clinical signs and symptoms of coronary disease. We do not know what regulates the concentration of the lipoprotein in plasma, but it appears to be under strong genetic control. 24 HDL functions as the initiator of 'reverse cholesterol transport', promoting the clearance of sterol from peripheral tissues to the liver. This role underlies the inverse relationship between the plasma level of the lipoprotein and coronary heart disease. Many subjects with IHD have low HDL cholesterol, often as the only lipoprotein abnormality present. However, it usually appears in association with a raised plasma triglyceride concentration. In fact, the metabolism of HDL is closely linked to that of the triglyceride-rich lipoproteins; they exchange both 'core' and 'coat' components and, to a large extent, HDL is derived from the lipolysis of chylomicrons and VLDL. Cholesterol is mobilized from tissues when HDL binds to the cell membrane and incorporates excess unesterified sterol into its surface monolayer. The nature of the binding site is controversial, and as yet it is uncertain whether it is a specific protein receptor as in the case of LDL.25 In vivo, free cholesterol acquired by HDL is rapidly esterified by lecithincholesterol acyl transferase (LCAT). The action of this enzyme traps the sterol moiety in the core of the lipoprotein and permits the capture of more cellular cholesterol. Repeated cycles of absorption and esterification lead to expansion of the HDL core and an increase in particle size.
As a result, smaller HDL in the HDL3 subfraction are converted to the larger, less dense HDL2-
The fate of cholesterol accumulated in the HDL fraction is not entirely clear. In some species, like the rat, HDL is thought to be cleared directly by the liver; however in others, including man, another plasma factor, cholesteryl ester transfer protein (CETP), operates to transfer ester from HDL to triglyceride-rich lipoproteins. These may be the final vehicles that carry cholesterol back to the liver. 26 The extent of the transfer is dependent on both the activity of CETP and the concentration of acceptor lipoproteins. 27 For example, in hypertriglyceridaemic subjects, VLDL has a high content of cholesteryl ester while HDL receives triglyceride in exchange, and its core is enriched in the lipid. This renders HDL susceptible to lipolysis by hepatic lipase, an enzyme located on hepatic sinusoidal endothelial cells. It is able to convert HDL2 back to HDL3 and is a major regulator of the HDL2 concentration in plasma. 28 The higher level of HDL2 in women is to a large extent attributable to their lower hepatic lipase activity. The activity of the enzyme and HDL cholesterol levels are influenced by sex hormones and by certain hypolipidaemic drugs. 8
Both low and high HDL levels can be inherited. Recent studies from this and another laboratory29 have uncovered a strong genetic link between variation in the CETP gene and HDL cholesterol. We examined DNA from subjects with high (> 2.0mmol/l) and low (< l.Ommol/1) HDL levels. Restriction fragment length polymorphisms (RFLPs) were observed in the genes coding for apolipoprotein-AI, LCAT and CETP. None of the AI or LCAT variants were related to HDL cholesterol, but the TaqIB RFLP in the CETP gene was strongly linked to both the cholesterol and AI29 components of HDL. Subjects with the cutting site for the enzyme were likely to have higher plasma concentrations of HDL cholesterol and apoAI. Interestingly, this inherited tendency to high HDL levels is abolished by cigarette smoking. 29
Triglyceride-rich lipoproteins and atherosclerosis
The importance of triglyceride as a risk factor for IHD has been debated for many years. In cross-sectional and longitudinal studies it consistently shows a positive association with coronary disease, but when multivariate analysis is used to include the influence of other factors, especially HDL, it no longer appears as an independent correlate for IHD. However, this statistical approach has been questioned, and alternative analyses place greater emphasis on triglyceride.3° Certainly, clinical trials in which this lipid has been reduced have had positive outcomes, with reduced myocardial infarction rates in the treated group. 31,32 In the Swedish secondary prevention stud y32 the benefit of lipidlowering treatment was linked more to the fall in triglyceride than any change in plasma cholesterol. Triglyceride itself need not be considered atherogenic; it acts as a marker for the plasma concentrations of chylomicrons and VLDL, both of which have a substantial content of free and esterified cholesterol. Indeed, due to their rapid turnover it can be calculated that a significant amount of sterol fluxes through these lipoprotein species.33 Additionally, the presence of high plasma triglyceride levels perturbs the structure of LDL and HDL towards a more atherogenic profile.
Chylomicrons are synthesized in the gut during the absorption of dietary fat; they pass into the systemic circulation and their core triglyceride is removed by the action of lipoprotein lipase. Cholesteryl ester remains with the particle and is added to by CETP-mediated transfer from HDL. The extent of sterol ester accumulation in chylomicrons depends on their residence time in the plasma, which is in turn heavily influenced by lipoprotein lipase activity. A prolonged circulation time leads to cholesteryl ester-rich chylomicrons and triglyceride-enriched HDL. As noted above, the latter are susceptible to lipolysis, lowering the concentration of HDL in the plasma.
When the majority of triglyceride is removed from chylomicrons they are termed 'remnants'. Normally these are rapidly removed from the circulation by the liver, but their clearance is delayed in subjects with coronary disease who, as a result, exhibit high levels of chylomicron remnants in their bloodstream.34 These remnants seem to be particularly atherogenic. Of all the lipoproteins found in plasma, they are the ones most able to induce cholesteryl ester deposition in cultured macrophages.35 Recent studies from our laboratory have examined chylomicron metabolism in control and diseased subjects. A fat-load test was administered early in the morning, and the generation of lipaemia followed over the course of the day. Those positive for coronary disease showed a higher peak level of plasma triglycerides and a slower clearance than their healthy counterparts. Subsequent fat-load tests after eight weeks of fenofibrate therapy demonstrated that this treatment improved the ability to handle dietary fat (CJ Packard, J Shepherd, unpublished). Future prospects for the detection and treatment of atherosclerosis It is clear from the above discussion that we can go much further than simple cholesterol measurement in determining an individual's risk of developing heart disease. However, the widespread application of many of the tests described above must await the development of new technology. Meanwhile, better use could be made of existing methods for the fractionation of plasma cholesterol into VLDL, LDL and HDL. This would improve characterization of patients who were candidates for life-long lipidlowering therapy, and aid in assessing the worth of the various pharmaceutical agents available. Not all drugs are equally applicable to the different hyperlipidaemic situations: for example, cholestyramine should not be used where there is significant hypertriglyceridaemia since it aggravates the condition. This agent is most suited for treatment of the type IIa hyperlipoproteinaemic phenotype. On the other hand, gemfibrozil has been shown3l to benefit subjects with raised triglyceride and low HDL, (i.e. type lib and type IV phenotypes), but is less helpful in those with increases in LDL alone. Experience acquired over the next few years with new agents like the HMG CoA reductase inhibitors and with older agents used singly and in combination should permit a more rational approach to the treatment of hyperlipidaemia. This is essential in order to meet the more aggressive therapeutic goals that have been suggested as necessary to halt or even reverse the process of atherosclerosis.
Expert Committees in the USA, Europe and the UK have met to establish desirable limits for the levels of plasma lipids in western populations. These are summarized in Table 1 . Associated with each category of risk is a recommended approach to treatment. These 'action limits' have largely replaced reference ranges in the reporting of lipid and lipoprotein analysis from many clinical chemistry laboratories in the UK. Obviously they are meant as guidelines and must be applied in the context of the individual patient's situation.
The outcome of a growing series of lipidlowering clinical trials indicates that attainment of therapeutic goals in subjects with raised cholesterol and triglyceride can produce substantial benefit in reducing at least coronary Table 1 Action levels for plasma lipids at SAGE PUBLICATIONS on December 9, 2012 vmj.sagepub.com Downloaded from morbidity if not mortality. The Lipid Research Clinics Coronary Primary Prevention Trial9 demonstrated for the first time a significant reduction in fatal and nonfatal myocardial infarction in subjects given cholestyramine, compared to those receiving placebo. This drug lowers LDL specifically by activation of receptormediated catabolism in the liveer. 36 The gradient of clinical benefit was steep: for every 1 % fall in LDL cholesterol there was a 2% decline in the incidence of coronary events. Those who took the maximum dose of cholestyramine experienced a 25% reduction in LDL, and half the rate of infarction seen in the placebo group. Results from the Helsinki Heart Study31 were similarly encouraging. The agent used in this trial was gemfibrozil, a member of the fibrate family of lipid-lowering drugs. Application was associated with 34% fewer myocardial infarctions compared to placebo. As with the LRC study there was a two-year lag before benefit was seen, and over the final three years of the trial an impressive 50% difference in event rates was observed.
Gemfibrozil, like other fibrates, is most effective at lowering plasma triglyceride and VLDL concentrations, accompanied by a fall in LDL and a rise in HDL. The results of the Helsinki study indicate that the patients who benefit most from fibrate therapy are those who present with the 'raised triglyceride/low HDL' risk pattern.
Angiographic studies of the effects of lipidlowering agents on coronary atherosclerosis indicate that the above benefits are probably associated with stasis, (i.e. lack of progression), of coronary lesions. The results of the NHLBI type II secondary intervention stud y37 demonstrated that cholestyramine therapy was usually associated with no-change in lesion number and size rather than regression. It was the Cholesterol Lowering Atherosclerosis Study (CLAS )28 that provided evidence that regression could occur, but only in the face of much greater plasma lipid reductions than those seen in the LRC or Helsinki studies. A combination of a bile acid sequestrant resin and niacin was used in CLAS to produce a 22% reduction in triglyceride, a 43% reduction in LDL and a 37% increase in HDL in coronary bypass-grafted subjects. While the majority of the drug-treated group showed little change in lesion size, 16% experienced measurable regression of atheroma.
Interestingly, the benefit of these lipid changes was observed even in those who initially had plasma cholesterol and triglyceride levels within the normal range.
The advent of highly potent cholesterollowering agents -the statinsprovides the prescribing physician with the ability to produce marked LDL lowering in virtually all hypocholesterolaemic patients, reductions of 30-70% in LDL being readily achieved. This degree of control opens new possibilities for the prevention of IHD.
